Study guide

3.1 Karyotype, FISH & Chromosomal Microarray

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

3.1 Karyotype, FISH & Chromosomal Microarray

Key Takeaways Explain This Topic AI

Conventional G-banded karyotype resolves large chromosomal changes (roughly 5–10 Mb) and uniquely detects balanced rearrangements that microarray cannot see.

FISH uses locus-specific probes for rapid targeted questions (aneuploidy screens, known microdeletion loci) but does not provide a genome-wide survey.

Chromosomal microarray (CMA) detects copy-number variants at kilobase-to-megabase resolution and, on SNP platforms, can flag regions of homozygosity—yet it misses balanced rearrangements.

Low-level mosaicism can be under-detected by any single cytogenetic modality; percent mosaicism and tissue distribution matter for phenotype and counseling.

Method choice is indication-driven: suspected aneuploidy or balanced rearrangement → karyotype/FISH pathway; unexplained developmental delay or multiple congenital anomalies → CMA first-line in many pediatric algorithms.

Last updated: August 2026

Why cytogenetic methods still matter

Domain 3A expects you to choose and counsel cytogenetic technologies with the same rigor you apply to NGS. Families often arrive with a report labeled “chromosome study,” “FISH,” or “microarray” and assume these tests are interchangeable. They are not. Each modality answers a different structural question at a different resolution , with different false-negative classes . Your job is to connect the indication (aneuploidy, microdeletion syndrome, balanced translocation carrier status, unexplained developmental delay) to the right first-line test—and to explain limitations before results return.

Conventional karyotype (G-banded chromosome analysis)

A karyotype examines metaphase chromosomes after culture, harvesting, and banding (typically G-banding with trypsin–Giemsa). Chromosomes are counted and scrutinized for large gains/losses and structural rearrangements.

Feature Practical range / implication

Resolution Roughly 5–10 Mb for reliable detection of many imbalances (band-level, platform- and quality-dependent)

Detects Aneuploidy, large deletions/duplications, balanced translocations and inversions, many ring chromosomes, marker chromosomes (with limits)

  • Requires Dividing cells (blood, amniotic fluid culture, CVS culture, tissue culture)
  • Turnaround Days to weeks depending on culture success and indication
  • Key strength Only common genome-wide cytogenetic method that visualizes balanced rearrangements

Key limitation Misses most microdeletions/microduplications below resolution; cryptic rearrangements; some tissue culture failures

When karyotype is the right tool

Suspected aneuploidy with need for structural characterization (e.g., distinguishing free trisomy 21 from translocation Down syndrome for parental recurrence counseling).

Known or suspected balanced rearrangement in a parent (recurrent pregnancy loss, family history of rearrangement) where microarray alone would be falsely reassuring.

Characterization of a marker chromosome or complex rearrangement after an abnormal CMA or FISH finding.

Exam trap: Ordering CMA alone when the clinical question is “Is this parent a balanced translocation carrier?” CMA does not answer that question.

FISH (fluorescence in situ hybridization)

FISH hybridizes fluorescent DNA probes to metaphase or interphase nuclei to ask a targeted locus question.

  • FISH mode Use case
  • Metaphase FISH Confirm rearrangements, map breakpoints relative to known probes, clarify marker chromosomes

Interphase FISH Rapid aneuploidy panels (e.g., chromosomes 13, 18, 21, X, Y); tissue that does not culture well

Locus-specific probes Known microdeletion/duplication syndromes (e.g., 22q11.2) when that single locus is the clinical question

Strengths and blind spots

Strength: Fast, targeted, excellent when you already know which locus matters.

Blind spot: FISH does not scan the rest of the genome. A negative 22q11.2 FISH does not exclude other pathogenic CNVs.

Probe design matters: If a deletion is atypical and lies outside the probe region, FISH can be falsely negative relative to CMA coverage of that interval.

Use FISH as a precision tool , not as a substitute for genome-wide copy-number assessment when the phenotype is nonspecific.

Chromosomal microarray (CMA)

Chromosomal microarray (oligonucleotide array CGH, SNP array, or combined platforms) detects copy-number variants (CNVs) at much finer resolution than karyotype—often in the kilobase to low-megabase range depending on probe density and laboratory thresholds.

  • Capability CMA Karyotype
  • Genome-wide CNV detection Yes (platform-dependent resolution) Limited to large imbalances
  • Balanced translocation / inversion No (copy-neutral) Yes (if visible)
  • Aneuploidy Yes Yes

Low-level mosaicism Variable; often less sensitive than karyotype for very low-level clones Better for some mosaic aneuploidies if clone divides

  • Regions of homozygosity (ROH/AOH) SNP arrays can detect No
  • Triploidy / some polyploidy Platform-dependent; SNP data help Often apparent on karyotype
  • The balanced-rearrangement rule (board-critical)

Because CMA measures dosage , a balanced reciprocal translocation or inversion that does not change copy number is typically invisible . A person can be a balanced carrier, have recurrent pregnancy loss or an unbalanced offspring, and still have a normal microarray . Teach this explicitly in pretest counseling whenever reproductive or familial rearrangement risk is on the differential.

SNP array bonuses and caveats

SNP-based arrays can reveal regions of homozygosity , which may suggest identity by descent (consanguinity), uniparental disomy (UPD) suspicion for a chromosome, or other mechanisms—interpretation is clinical and often requires follow-up (methylation testing, UPD studies, or sequencing), not automatic diagnosis from ROH alone.

Mosaicism (note now; prenatal CPM detail later)

Mosaicism —two or more genetically distinct cell lines—can be missed or under-quantified by any modality:

Karyotype may detect mosaic aneuploidy if the abnormal line grows in culture, but culture can select for or against clones.

CMA may miss low-level mosaicism below the lab’s detection threshold.

FISH can quantify mosaicism at a targeted locus in many cells but still misses untargeted changes.

Counsel that a “normal” cytogenetic result reduces but does not always eliminate mosaic disease, especially when phenotype is highly suggestive. Detailed confined placental mosaicism (CPM) counseling belongs with prenatal diagnostic chapters; here, remember that tissue source and mosaicism affect what blood-based cytogenetics can show.

Choosing among karyotype, FISH, and CMA

  • Clinical question Prefer
  • Nonspecific DD/ID, multiple congenital anomalies (pediatric first-line CNV evaluation) CMA

Classic aneuploidy phenotype needing structural classification (translocation vs free trisomy) Karyotype (± FISH)

  • Rapid targeted aneuploidy or known microdeletion locus FISH (then confirm/expand as needed)
  • Recurrent miscarriage / suspected balanced carrier Karyotype (not CMA alone)
  • Clarify a CMA CNV at a known syndrome locus Targeted FISH or orthogonal method per lab
  • Common counseling traps

Equating “chromosomes normal” on CMA with “no chromosomal problem”—balanced rearrangements and some mosaicism remain possible.

Using FISH as a genome-wide screen.

Ignoring that variant of uncertain significance (VUS) CNVs on CMA require phenotype correlation, inheritance studies, and careful language—not automatic pathogenicity.

Forgetting that culture failure or poor DNA quality can delay or cancel cytogenetic testing—plan sample type accordingly (next section).

Integrating cytogenetics into the testing pathway

Cytogenetics and molecular sequencing are complementary, not competitors. A child with developmental delay may start with CMA; a negative CMA does not exclude sequence-level Mendelian disease (exome/genome). Conversely, an exome that misses a large multi-exon deletion may need CNV-aware analysis or CMA/MLPA. On the CGC exam, stems often turn on whether the missing piece is copy-number, balanced structure, or sequence—and whether the ordered test can see that piece.